Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice

doi:10.1016/S0304-3940(02)00069-1

Neuroscience Letters

Volume 322, Issue 1, 29 March 2002, Pages 13-16

https://doi.org/10.1016/S0304-3940(02)00069-1 Get rights and content

Abstract

We investigated the effect of chronic daily caffeine treatment on caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity. Mice received either caffeine (20 mg/kg) or saline daily for 9 days. Caffeine-induced locomotion tolerance developed within 3 days of treatment and persisted for the duration of the experiment. On day 10, mice were treated with MPTP (20 mg/kg, ×4). Caffeine (20 mg/kg) or saline was administered 10 min before each MPTP dose. Acute pretreatment with caffeine attenuated MPTP-induced loss of striatal dopamine and dopamine transporter binding sites, and this attenuation was identical in mice pretreated chronically with caffeine or with saline. Thus, in contrast to the locomotor stimulant effect of caffeine, its neuroprotectant effect did not show tolerance to prior caffeine exposure. These data raise the possibility that caffeine may induce neuroprotection and locomotion by distinct mechanisms.

Section snippets

Acknowledgements

This work was supported by grants from the NIH (NS37403, AG18167 and ES10804) and the American Parkinson Disease Association (Cotzias Fellowship).

References (20)

L. Halldner et al.
Lack of tolerance to motor effects of a selective adenosine A2A receptor antagonist
Eur. J. Pharmacol.
(2000)
K.A. Jacobson et al.
Adenosine receptor ligands: differences with acute versus chronic treatment
Trends Pharmacol. Sci.
(1996)
P. Popoli et al.
Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats
Eur. J. Pharmacol.
(1995)
A.M. Sebastiao et al.
Adenosine A2 receptor-mediated excitatory actions on the nervous system
Prog. Neurobiol.
(1996)
P. Svenningsson et al.
Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens
Neuroscience
(1997)
H. Tsuda et al.
Heterocyclic amine mixture carcinogenesis and its enhancement by caffeine in F344 rats
Cancer Lett.
(1999)
A. Ascherio et al.
Prospective study of caffeine intake and risk of Parkinson's disease in men and women
Ann. Neurol.
(2001)
M.D. Benedetti et al.
Smoking, alcohol, and coffee consumption preceding Parkinson's disease. A case–control study
Neurology
(2000)
J.F. Chen et al.
Neuroprotection by caffeine and A_2A adenosine receptor inactivation in a model of Parkinson's disease
J. Neurosci.
(2001)
K.T. Delle Donne et al.
Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation
J. Pharmacol. Exp. Ther.
(1994)

There are more references available in the full text version of this article.

Cited by (93)

Adora2A downregulation promotes caffeine neuroprotective effect against LPS-induced neuroinflammation in the hippocampus
2024, Brain Research
Caffeine has been extensively studied in the context of CNS pathologies as many researchers have shown that consuming it reduces pro-inflammatory biomarkers, potentially delaying the progression of neurodegenerative pathologies. Several lines of evidence suggest that adenosine receptors, especially A₁ and A₂A receptors, are the main targets of its neuroprotective action. We found that caffeine pretreatment 15 min before LPS administration reduced the expression of Il1b in the hippocampus and striatum. The harmful modulation of caffeine-induced inflammatory response involved the downregulation of the expression of A₂A receptors, especially in the hippocampus. Caffeine treatment alone promoted the downregulation of the adenosinergic receptor Adora2A; however, this promotion effect was reversed by LPS. Although administering caffeine increased the expression of the enzymes DNA methyltransferases 1 and 3A and decreased the expression of the demethylase enzyme Tet1, this effect was reversed by LPS in the hippocampus of mice that were administered Caffeine + LPS, relative to the basal condition; no significant differences were observed in the methylation status of the promoter regions of adenosine receptors. Finally, the bioinformatics analysis of the expanded network demonstrated the following results: the Adora2B gene connects the extended networks of the adenosine receptors Adora1 and Adora2A; the Mapk3 and Esr1 genes connect the extended Adora1 network; the Mapk4 and Arrb2 genes connect the extended Adora2A network with the extended network of the proinflammatory cytokine Il1β. These results indicated that the anti-inflammatory effects of acute caffeine administration in the hippocampus may be mediated by a complex network of interdependencies between the Adora2B and Adora2A genes.
Caffeine alleviates anxiety-like behavior and brainstem lesions in a rotenone-induced rat model of Parkinson's disease
2023, Journal of Chemical Neuroanatomy
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms. In 2016, approximately 6.1 million individuals were affected by PD, with 211,296 deaths attributed to the disease. The understanding of PD initially came from the observation of dopaminergic system alterations in a specific region of the brainstem, indicating that the core motor and non-motor features of PD are closely associated with brainstem dysfunction. The primary treatment approach for PD revolves around dopamine replacement, as many of the symptoms are responsive to this therapeutic intervention. However, long-term administration of this approach is linked to several complications, and a definitive gold-standard therapy for PD is yet to be identified. The pharmacological management of PD has been challenging and inconsistent, mainly due to the unclear underlying cause of the disease. This study aims to evaluate the effects of caffeine on the brainstem of rats with PD induced by rotenone.
Fifty adult male Wistar rats weighing between 150 and 200 g were used in this study. The rats were randomly divided into five groups of ten rats each: Vehicle Group, Rotenone-only treated Group (rotenone only treated with 3 mg/kg, intraperitoneal administration [IP]), Preventive Group (caffeine 30 mg/kg + rotenone 3 mg/kg, IP), Curative Group (rotenone 3 mg/kg + caffeine 30 mg/kg, IP), and Caffeine only treated Group (caffeine only treated with 30 mg/kg, IP). The animals underwent neurobehavioral assessments, followed by sacrifice. The brains were then excised, weighed, and processed histologically. Appropriate brain sections were taken and processed. Photomicrographs were obtained, morphometric and statistical analysis was performed using an Omax LED digital
The results demonstrated a significant (p < 0.05) reduction in body weight and relative brain weight, which were increased by caffeine treatments. Rotenone administration led to histological changes similar to those observed in PD, including neuronal structural derangement, degenerated nerve fibers, loss of myelinated neurons, and Nissl substance, as well as downregulation in the expressions of NRF2 and TH in the midbrain. However, these pathological features were counteracted or ameliorated by caffeine treatment.
Our study contributes additional evidence to the growing body of research supporting the therapeutic potential of caffeine in Parkinson's disease (PD). The results underscore the neuroprotective properties of caffeine and its capacity to mitigate oxidative stress by modulating TH (tyrosine hydroxylase) and cytoplasmic NRF2 (nuclear factor erythroid 2-related factor 2) in the mesencephalon. These findings suggest that caffeine holds promise as a viable treatment option for PD.
Targeting the adenosine A<inf>2A</inf> receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson's disease
2023, Chinese Journal of Traumatology - English Edition
Adenosine exerts its dual functions of homeostasis and neuromodulation in the brain by acting at mainly the two G-protein coupled receptors, called A₁ and A_2A receptors. The adenosine A_2A receptor (A_2AR) antagonists have clinically pursued for the last two decades, leading to final approval of the istradefylline, an A_2AR antagonist, for the treatment of OFF-Parkinson's disease (PD) patients. The approval paves the way to develop novel therapeutic methods for A_2AR antagonists to address two major unmet medical needs in PD and traumatic brain injury (TBI), namely neuroprotection or improving cognition. In this review, we first consider the evidence for aberrantly increased adenosine signaling in PD and TBI and the sufficiency of the increased A_2AR signaling to trigger neurotoxicity and cognitive impairment. We further discuss the increasing preclinical data on the reversal of cognitive deficits in PD and TBI by A_2AR antagonists through control of degenerative proteins and synaptotoxicity, and on protection against TBI and PD pathologies by A_2AR antagonists through control of neuroinflammation. Moreover, we provide the supporting evidence from multiple human prospective epidemiological studies which revealed an inverse relation between the consumption of caffeine and the risk of developing PD and cognitive decline in aging population and Alzheimer's disease patients. Collectively, the convergence of clinical, epidemiological and experimental evidence supports the validity of A_2AR as a new therapeutic target and facilitates the design of A_2AR antagonists in clinical trial for disease-modifying and cognitive benefit in PD and TBI patients.
Caffeine, a natural methylxanthine nutraceutical, exerts dopaminergic neuroprotection
2021, Neurochemistry International
Citation Excerpt :
Neuro-nutraceuticals contain naturally occurring alkaloids, which improve mental health. Some of the know neuro-nutraceutical are coffee (caffeine), capsicum, fruits and vegetables (Quercetin), broccoli (Sulforaphane), turmeric (curcumin), grape (resveratrol), mucuna pruriens (L-DOPA), ginseng, green tea (catechins), fermented products (Synbiotic such as prebiotic, Probiotic) (Chakraborty et al., 2015; Dutta and Mohanakumar, 2015; Gazaryan and Thomas, 2016; Karuppagounder et al., 2009; Mandel and Youdim, 2004; Manyam et al., 2004; Mishra and Palanivelu, 2008; Van Kampen et al., 2003; Williams et al., 2015, 2016; Xu et al., 2002). Nutraceutical-derived formulations modulate inflammation pathways, cell survival and division, cell homeostasis (micronutrition), and maintenance of gut microbial (Markowiak and Slizewska, 2017).
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects more than 10 million people worldwide. Oxidative stress and mitochondrial dysfunction play a significant role in altering the homeostasis of energy production and free radical generation. Current PD therapies are focused on reducing the cardinal symptoms rather than preventing disease progression in the patients. Adenosine A_2A receptor (A_2A R) antagonist (Istradephylline) combined with levodopa shows a promising therapy for PD. In animal studies, caffeine administration showed to improve motor functions and neuroprotective effect in the neurons. Caffeine is probably the most extensively used psychoactive substance. In this current study, we investigated the neuroprotective effect of caffeine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration. Here, we demonstrate that caffeine improves behavioral and neurotransmitter recovery against MPTP-induced toxicity. Caffeine restores endogenous antioxidant levels and suppresses neuroinflammation. Our finding suggests that the blockage of A_2AR is a promising disease-modifying therapy for PD. Target engagement strategies could be more beneficial in preventing disease progression rather than symptomatic reliefs in PD patients.
Do caffeine and more selective adenosine A<inf>2A</inf> receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?
2020, Parkinsonism and Related Disorders
Citation Excerpt :
The first experimental evidence for a neuroprotective effect of A2A receptor antagonists including caffeine arose 20 years ago with the demonstration that genetic inactivation and pharmacological blockade of the A2A receptor attenuate dopaminergic neurotoxicity and neurodegeneration in rodent models of parkinsonism. These models were created using mitochondrial toxins (systemically-administered MPTP and brain infusion of 6-OHDA), which produce relatively selective neuronal cell death [39–41]. A2A receptor antagonist-mediated neuroprotection against dopaminergic neurodegeneration has been confirmed by follow-up studies and has been extended to other neurotoxin models of PD, such as the rotenone rat PD model [42,43].
The adenosine A_2A receptor is a major target of caffeine, the most widely used psychoactive substance worldwide. Large epidemiological studies have long shown caffeine consumption is a strong inverse predictor of Parkinson's disease (PD). In this review, we first examine the epidemiology of caffeine use vis-à-vis PD and follow this by looking at the evidence for adenosine A_2A receptor antagonists as potential neuroprotective agents. There is a wealth of accumulating biological, epidemiological and clinical evidence to support the further investigation of selective adenosine A_2A antagonists, as well as caffeine, as promising candidate therapeutics to fill the unmet need for disease modification of PD.
Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance
2020, Nutrition Research
Caffeine, a xanthine alkaloid compound, is consumed widely and daily by humans, as it is present in several regular beverages such as tea, coffee, soda beverages, and some drugs. Its consumption triggers arousal and alertness, improves mood, and causes the release of catecholamines, which induce beneficial effects on human behavior. Nonetheless, caffeine has been related to other beneficial effects such as antioxidant and anti-inflammatory actions that are extremely important to human health, altering the cellular redox and inflammatory status in a dose-dependent manner. Caffeine intake has also shown ergogenic effects, which are attributed to different factors, such as enhanced substrate utilization, fatigue delay, and alertness. As such, caffeine has been consumed by athletes from different sports modalities, with positive and negative effects declared. Although peripheral tissues such as the heart, skeletal muscle, and adipocytes are also impacted, there is a deficit of recognized mechanisms in systemic metabolism when compared to caffeine action in the central nervous system. This review summarizes the most relevant classical and current literature available regarding the use of caffeine in different metabolic situations, such as oxidative and inflammatory status, as well as anaerobic and aerobic physical exercises. Here, we identified the non–central nervous system caffeine mechanisms modulation, as most are still unknown or controversial, highlighting its influence in the peripheral system and its essential and crucial impacts on the human’s organism adaptation.

View all citing articles on Scopus

View full text

Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice

Abstract

Section snippets

Acknowledgements

Eur. J. Pharmacol.

Trends Pharmacol. Sci.

Eur. J. Pharmacol.

Prog. Neurobiol.

Neuroscience

Cancer Lett.

Prospective study of caffeine intake and risk of Parkinson's disease in men and women

Ann. Neurol.

Smoking, alcohol, and coffee consumption preceding Parkinson's disease. A case–control study

Neurology

Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease

J. Neurosci.

Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation

J. Pharmacol. Exp. Ther.

Neuroprotection by caffeine and A_2A adenosine receptor inactivation in a model of Parkinson's disease